Overview

A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting

Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
This study is looking at a range of doses of this NK-1 receptor antagonist drug, for both safety and effectiveness in prevention PONV
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Ondansetron